Grifols reported EUR5.96B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 666K 304K Jun/2026
Arca Biopharma USD 941.49M 56.93M Sep/2026
aTyr Pharma USD 50.16M 8.21M Sep/2026
Bio Path USD 677K 14K Mar/2026
Brainstorm Cell Therapeutics USD 316K 132K Jun/2026
Capricor Therapeutics USD 202.25M 39.88M Sep/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Grifols EUR 5.96B 316.31M Dec/2025
Immunic USD 135.09M 22.75M Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024